Sermorelin is the GHRH(1-29) analog studied for the growth-hormone axis and cognition in older adults.

The short version

Sermorelin is a lab-made copy of the first 29 building blocks of growth hormone-releasing hormone (GHRH) — the natural signal your brain uses to tell the pituitary gland to release growth hormone. Instead of injecting growth hormone directly, sermorelin asks the body to make its own, so the body's normal on-off controls stay in charge. It was a prescription medicine for short children decades ago, was pulled from the US market in 2008 for business reasons, and is now made by compounding pharmacies. Studies measured real effects on growth hormone, IGF-1, and — for a close relative — cognition. The anti-aging marketing, though, runs ahead of the evidence.

Sermorelin, the GHRH(1-29) peptide

Sermorelin (also written GHRH(1-29)NH2, GRF(1-29), or sermorelin acetate) is a synthetic 29-amino-acid peptide — a short chain of 29 protein building blocks. It corresponds to the amino-terminal 1-29 fragment of the body's own 44-residue growth hormone-releasing hormone, and it is the shortest fragment that keeps full activity at the GHRH receptor ^[11][14]. As a sermorelin peptide, it is supplied as a lyophilized (freeze-dried) powder of the acetate salt, molecular weight 3357.9 Da, CAS 86168-78-7.

The naming matters because the chemistry is the whole story. Native GHRH is a hormone the hypothalamus releases in pulses; sermorelin is the part of that hormone the pituitary actually reads. Keeping only 29 of the 44 residues was a deliberate pharmacological choice — it preserves the active end of the molecule while making a defined, manufacturable peptide ^[14]. Everything downstream — the growth-hormone pulse, the rise in IGF-1, the cognition signal in related analogs — follows from that receptor-binding event.

A practical note on the name: "sermorelin" the research compound, the historically approved pediatric medicine, and the compounded preparation sold today are the same molecule used in different contexts. This site treats it as a research subject and a piece of regulatory history, not as a product to take.

Sermorelin mechanism of action

The sermorelin mechanism of action is upstream stimulation of the pituitary, not replacement of growth hormone. Sermorelin binds the GHRH receptor (GHRH-R, a class B G-protein-coupled receptor — a switch on the cell surface) on anterior-pituitary somatotrophs, the growth-hormone-producing cells. Receptor binding activates the Gs / adenylate cyclase / cAMP / protein kinase A pathway — a relay inside the cell that raises a second messenger called cAMP — which increases growth-hormone gene transcription and triggers release of stored growth hormone ^[11].

Because sermorelin acts on the gland rather than supplying hormone from outside, the body's own brakes stay connected. Somatostatin (the hypothalamic "stop" signal) and IGF-1 negative feedback continue to regulate output, so growth hormone is released in the natural pulsatile pattern rather than a flat, constant level ^[11][13]. Pulse timing matters: pulsatile delivery of GHRH preserved the growth-hormone response far better than a continuous infusion in normal men, which is why intermittent dosing — not a steady drip — is the studied pattern ^[12].

This is the editorial argument advanced for sermorelin: a physiologic secretagogue (a compound that stimulates the body's own secretion) may be a more physiologic approach to adult-onset growth-hormone insufficiency than recombinant growth hormone, precisely because feedback and pulsatility remain intact ^[4]. It is an argument from mechanism, not a proof of clinical benefit.

What sermorelin is studied for

When people search sermorelin benefits, they are usually asking what the literature actually measured. Four research areas dominate, and they vary sharply in evidence strength.

Pediatric growth (its approved use, now historical). In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth — first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation ^[1]. This is the strongest, most clearly indicated evidence in the file.

The adult GH/IGF-1 axis. In healthy older men (mean 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour growth hormone and IGF-1; after high-dose treatment, those parameters no longer differed from young men, with no change in fasting glucose ^[2].

Cognition. A 152-person randomized, placebo-controlled trial of a daily GHRH analog reported a favorable effect on cognition (P=0.03) over 20 weeks ^[6] — the dealt thread this board follows through the GHRH(1-29) research record.

Body composition and sleep round out the studied areas. None of this establishes a general adult anti-aging benefit, and an Annals of Internal Medicine editorial judged growth-hormone-secretagogue use for aging "not yet ready for prime time" ^[5]. The marketing outpaces the evidence; this site keeps them separate.

Formerly FDA-approved, now compounded — the distinction this site insists on

Sermorelin's regulatory history is frequently misstated, so it is worth stating precisely. Sermorelin acetate was once FDA-approved (NDA 020443) for the evaluation and treatment of growth-hormone deficiency and short stature in children. It was withdrawn from the US market in 2008 for commercial reasons — not safety or efficacy problems ^[5]. It is not a banned or unsafe drug; it simply stopped being sold as a branded product.

Today sermorelin is prepared by compounding pharmacies. It is treated as a long-standing Category 1 bulk drug substance under FDA's interim Section 503A policy, with final guidance in January 2025; FDA does not intend enforcement action against Category 1 compounding. That status is distinct from other growth-hormone-axis peptides reviewed by the Pharmacy Compounding Advisory Committee in October 2024, and the two should not be conflated.

The domain says "medicine," and the careful reading is this: sermorelin was a medicine, is studied as a research compound, and is available compounded — but research-grade material described here is not presented as a current medicine to take. "Formerly FDA-approved, now compounded" is the accurate frame. For tolerability, see sermorelin side effects; for the published trials, see cited studies and references.

How does sermorelin work to stimulate growth hormone production?

It binds the GHRH receptor — a class B G-protein-coupled receptor — on pituitary somatotrophs, activating adenylate cyclase / cAMP / PKA signaling to increase growth-hormone synthesis and pulsatile release, which then drives hepatic IGF-1 ^[11]. All of this proceeds under preserved somatostatin and IGF-1 feedback, so the rise stays within physiologic bounds rather than overriding the body's controls ^[13].

What is sermorelin?

Sermorelin (GHRH(1-29)NH2 / GRF(1-29), sermorelin acetate) is a synthetic 29-amino-acid fragment of growth hormone-releasing hormone — the shortest fragment that retains full GHRH activity — and a pituitary growth-hormone secretagogue ^[14]. It mimics the body's own hypothalamic GHRH signal, whose growth-hormone-driving activity declines with age.

What does sermorelin do to the body?

It binds GHRH receptors on pituitary somatotrophs and stimulates the body's own pulsatile growth-hormone release, which raises hepatic IGF-1 while leaving somatostatin and IGF-1 feedback intact ^[11][2]. The effect is upstream and self-limiting: the gland is prompted, not overridden.

What is sermorelin used for?

Historically it was FDA-approved for the evaluation and treatment of growth-hormone deficiency and short stature in children (withdrawn from the US market in 2008 for commercial reasons) ^[1][5]. In research, GHRH(1-29) and its analogs have been studied in adult GH-axis, aging, cognition, sleep, and body-composition contexts ^[2][6].